id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-3334-0001,FDA,FDA-2026-N-3334,"Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and
Commitments; Availability",Notice,Announcement,2026-04-24T04:00:00Z,2026,4,2026-04-24T04:00:00Z,,2026-04-24T18:41:49Z,2026-08084,0,0,09000064b92a8592